top of page

Modality profile: Oncolytic Immunotherapies at #ASCO23

Replimune Founder and Head of R&D Robert Coffin describes the oncolytic immunotherapy approach to cancer research.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page